Alimentary Pharmacology and Therapeutics 2002: Vol 16 Index

27 Pages·2002·7.5 MB·English

Aliment Pharmacol Ther 2002; 16:
Index
'3C_octanoic breath test, 1341, 1481 \kkermans, L.M.A. see De Schryver, A.M.P.
3C_urea breath test, 553 \lampi, G. see Bazzoli. P.
4-aminosalicylic acid, 1771 albendazole, 595
5-aminosalicyclic acid, 647, 207 alcohol, 497, 985
5-HT, mechanisms, 225 alimentary diseases, 1709
5-HT, receptor antagonist, 119 \llan, A. see Hulin, S.J.
5-HT, receptors, 1563 allergies, 969
5-hydroxytryptamine, 623 Allez, M. see Sabate, J.M.
6-mercaptopurine, 647 dalosetron, 225, 985
6-thioguanine nucleotides, alverine citrate, 1187
12-month course, 243 amantadine, 2107
aminosalicylates, 79, 197
g-antagonist, 1801 \mlot, P.L. see Gordon, F.H.
a-4 integrin, 699 amoxicillin, ESS
a-tocopherol, 985 ampicillin, 1163
abdominal irradiation, 62 3 amylose-ethylcellulose coating, 1771
Abe, H. see Murakami, K. anal anastomosis, 27
Abitbol, V., Mary, J.Y., Roux, C., Soulé, J.C.. Belaiche, J.. anal fissures, 101
Dupas, J.-L., Gendre, J.P., Lerebours, E., Chaussade, S. & the \nderloni, A. see Parente, F.
Groupe d’ Etudes Thérapeutiques des Affections \ndreoli, A. see Armuzzi, A.
Inflammatoires Digestives (GETAID). Osteoporosis in \ndreu, V. see Calvet, X.
inflammatory bowel disease: effect of calcium and vitamin D Andriesse, G.I. see De Schryver, A.M.P.
with or without fluoride, 919 \ndriulli, A. see Perri, F.
absorption, 769 \ndus, T. see Musch, E.
ABT-229, 749, 1481 \nnese, V. see Rizzello, F.
acetaminophen, 707, 15 \nnibale, B., Di Giulio, E., Caruana, P., Lahner, E., Capurso, G.,
acid, 303, 1469 Bordi, C. & Delle Fave, G. The long-term effects of cure of
acid inhibition, 425 Helicobacter pylori infection on patients with atrophic body
acid secretion, 1723 gastritis, 1723
acidity, 455 \nnibale, B. see Lahner, E.
acute pancreatitis, 2097 Ansari, A., Hassan, C., Duley, J., Marinaki, A., Shobowale-Bakre,
Adachi, K., Ono, M., Kawamura, A., Yuki, M., Fujishiro, H. & E.-M., Seed, P., Meenan, J., Yim, A. & Sanderson, J. Thiopurine
Kinoshita, Y. Nizatidine and cisapride enhance salivary methyltransferase activity and the use of azathioprine in
secretion in humans, 297 inflammatory bowel disease, 1743
Adachi, K. see Hashimoto, T. antacids, 435, 2029
Adamo, S. see Rizzello, F. anterior cingulate cortex, 1357
Adams, G. see Malik, A.H. Anthony, A. see Wakefield, A.J.
adenosine triphosphate, 325 antibiotic prophylaxis, 727
adjuvant chemotherapy, 353 antibiotic therapy, 1715
adrenergic receptors, 1801 antibiotics, 291, 909, 1083, 1461
adverse effects, 27 antibiotics resistance, 793
Africa, 595 anticonvulsants, 1539
agents, 603 antidepressant, 1091
aging, 683 antidepressants, 1539
Ahmed, F. see Tutuian, R. antigens, 533
Ahn, D.S. see Choi, LJ. antioxidants, 197, 1997
Aichbichler, B. see Hégenauer, C. antisecretory agents, 1945
AIDS, 595, 799 antisense, 1761
Aisowmely, A.M. & Hodgson, H.J.F. Review article: non-surgical anti-TNF, 1101
treatment of hepatocellular carcinoma, 1 Antoni, I. see Feydt-Schmidt, A.
Akamatsu, T. see Futagami, S. antrum, 129
© 2002 Blackwell Science Ltd
INDEX
Barabino, A., Torrente, F., Ventura, A., Cucchiara, S., Castro, M
1PC2059, 40; & Barbera, C. Azathioprine in paediatric inflammatory bowel
\ppelman, S.A. see Huang, J.-Q. disease: an Italian multicentre survey, 1125
appropriateness, 1443 Barbera, C. see Barabino, A.
\ranha, G \vidan, B. Bargiggia, S. see Parente, F.
\rguedas, M.R. se Thompson, B.F. Barish, C. see Sands, B.E.
\rita, '] Murakami. K. Barish, C. see Yacyshyn, B.R.
Armuzzi Candelli, M., Zocco, M.A.., \ndreoli, A.. De Lorenzo, saron, J.H. & Sonnenberg, A. Alimentary diseases in the poor and
E.C., Miele, L., Cremonini, F., Cazzato, 1.A., Grieco, middle class in London 1773-1815, and in New York poor
. G. & Gasbarrini, A. Review article: breath 1797-1818, 1709
testing for human liver function assessment, 1977 Barrett's oesophagus, 735, 887, 893, 1795
\rnott, | Watts, D. & Ghosh, S. Review article: is clinical Barth, J.A. see Gardner, J.D.
optimum therapeutic goal in the treatment of Bartolozzi, F. see Cremonini, |
Crohn's disease? 857 Bartolozzi, F. see Di Caro, S.
\rnout an Hecken, A. Bashir, S., Gibril, F., Ojeaburu, J.V., Asgharian, B?. , Entsuah, L.K.,
\rrovo, M Serrano, P. Ferraro, G., Crafa, P., Bordi, C. & Jensen, R.T. Prospective study
\rtikis, V. see Georgopoulos, S.D. of the ability of histamine, serotonin or serum chromogranin A
\sano, 1 Saitoh, ‘| levels to identify gastric carcinoids in patients with
\scione, CC Gala, ¢ R¥ gastrinomas, | 367
\sgharian, B. see Bashir, S Basit, A.W. see Tuleu, C.
9, 1945 sasilisco, G. see Massironi, S.
. Chrysos, E. Zoras, Q.].. siaoussis, ]., Bates, J. see Rubin, G.
Karkavitsas, N. & Xynos, E. Octreotide enhances the BayerdoGrfler, E. see Malfertheiner, P.
accelerating effect of erythromycin on gastric emptying in Bazzoli, F., Zagari, R.M., Pozzato, P.. Fossi, S., Ricciardiello, L..
healthy subjects, 1563 Nicolini, G., De Luca, L., Berretti, D., Alampi, G., Di Pietro, C..
\therton, J.C. see Stack, W.A. Morelli, P. & Roda, E. Low-dose lansoprazole and
ae aS eae
atrophic body gastritis, 307, 1723 clarithromycin plus metronidazole vs. full-dose lansoprazole
atrophic gi and clarithromycin plus amoxicillin for eradication of
Helicobacter pylori infection, 153
Biichler, M.W. see Netzer, P.
beclometasone dipropionate, 1109
Belaiche. J. see Abitbol. V.
aulvomun Bella, M.R. see Calvet, X.
\venhaus Ullerich, H. Benito, R. see Lanas, A.
\vidan, | onnenberg, A., Bhatia, H. \ranha, G.. Schnell, T.G. Benson, M.]J. see Zar, S.
& Sontag Inguinal hernia is not a sign of colon cancer izodiazepines, 361, 1539
1 prospective screening trial, 1197 genheim, K. see Vakil. N.
ienberg, A., Schnell. T.G. & Sontag, S.J. There are rman, S. see Mayer, E.A.
ymptoms for erosive oesophagitis and Barrett’ mejo, F. see Boixeda, D.
endoscopic diagnosis is still essential, 735 nal, I. see Domenech,
lalfertheiner, P. sernard, B. see Goulenok, C.
¢ M1a son, J Bernard, D. see Van Vlierberghe, H.
Vo rghese, \ At. Bernasconi, G. see Ortiz, R.A.M.
Berretti, D. see Bazzoli, F.
beta-agonists, 1539
beta-antagonist, 1801
Bhat, K., Harper, A. & Gorard, D.A. Perceived food and drug
Baisley, allergies in functional and organic gastrointestinal disorders,
Baj. M 969
Bajador Bhatia, H. see Avidan, B.
Ball, D Biagini, R. see Bilardi, C.
balsalazide, Biagini, R. see Zentilin, P.
salzano, Bianchi Porro, G. see Parente, F.
Banna, N. see Langmead, L. Bianchi Porro, G. see Stockbriigger, R.W.
Jarabino, A '., Castellano, E., Gandullia, P., Calvi, A.. bicarbonate, 297
Cucchiara, le’Angelis, G.L.. Fontana, M., Lionetti, P., De Biemond, I. see Kamerling, 1.M.C.
Giacomo, C. & Gissi, A. The use of ciclosporin in paediatric bifidobacteria, 587, 1669
inflammatory bowel disease: an Italian experience, 1503 ?
2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2123-2148
INDEX
Bilardi, C. see Zentilin, P. ce, M. see Warrington, S.
Bilardi, C., Biagini, R., Dulbecco. P., liritano, E., Gambaro., C.., sozzola, L. see Fabris, P.
Mele, M.R., Borro, P., Tessieri, L., Zentilin, P., Mansi. C., Braden, B., Engholer, M.. Schaub, M., Usadel. K.-H., Caspary
Vigneri, S. & Savarino, V. Stool antigen assay (HpSA) is less & Lembcke, B. Long-term cisapride treatment improves
reliable than urea breath test for post-treatment diagnosis of diabetic gastroparesis but not glycaemic control, 134]
Helicobacter pylori infection, 17 >»?)
Bilardi, C. see Zentilin, P. Bredberg, E. see Hallerback, B.
biliary disease, 1037 Brenner, H. see Rothenbacher, D
biliary disorders, 1083 inkholf, H. see Chen, C.L.
bioartificial liver, 1547 Brinkmann, B.H. see Kuo, B.
biologic response modifier, 399 Brouwers, J.R.B.J. see Klok, R.M.
biological agents, 1579 Brown, J. see Mason, J.
bisacodyl, 1 327 Borsch, G. see Peitz, |
bismuth, 1457 Brullet, E. see Calvet. X
Bjorkman, D. see El-Serag. H.B. Bruno, see Gaeta, G.B
bleeding, 1137 Brz . A. see Tremaine. W.J
Bliesath, H. see Novick, J.
bloating, 225, 1867 Bujanda, L. see Elizalde. J.1
Blum, A.L. see Holtmann, G. B eraal, J. see Kamerling, I.M.C.
Blumer, J.L. see Orenstein, S.R. urke, T.A. see Goldstein, J.
Bochenek, W. see Kovacs, T.O.G. Burman, C.-F. see Malfertheiner, P.
Bochenek. W. see Tutuian, R. surton, D. see Kuo, B.
Bode, G. see Rothenbacher, D. Burton, D.D. see Cremonini, |
Boeckxstaens, G.E.E. see Hirsch, D.P. Buscarini, E. see Caletti, G.
Boeckxstaens, G.E.E. see Kuiken, S.D. Buti, M. see San Miguel, R.
soerr, I. see Sambuelli, A. but opolamine bromide
Boesiger, P. see Faas, H.
Bogers, J.J.P.M. see De Block, C.E.M svizer, P. see Holtmann, G
Boix. J. see Domenech, E. Bytzer, P. see Madsen, L.G
Boixeda, D.. Bermejo, F.. Martin-De-Argila, C., Lopez-Sanroman,
\., Defarges, V.. Hernandez-Ranz, F., Milicua, J.M. & Garcia C282Y,
Plaza, A. Efficacy of quadruple therapy with pantoprazole, Cabanne, A. see Sambuelli,sti }i l, A.
bismuth, tetracycline and metronidazole as rescue treatment Cabasés, J.M. see San Miguel, R.
for Helicobacter pylori infection, 1457 Cabré, E. see Domenech. E.
Bollani, S. see Stockbriigger, R.W. Ca 1021
Bommelaer, G. see Hallerback, B. idherin, 1O59
Bommelaer, G. see Marteau, P. Cadranel, J.F. see Goulenok, C.
Bonanno, G. see Caletti, G. aesomorphine, 663
Bondesen, S. see Schiodt, F.V.
bone, 919 % | see Van Den Bogaerde, J.
bone mineral density, 1519, 1895 ‘alafatti, S.A. see Ortiz, R.A.M.
Bonnet, J. see Sabate, J.M.
Bordi, C. see Annibale, B. iletti, G., Zinzani, P.L., Fusaroli, P., Buscarini, E., Parente, |
Bordi, C. see Bashir, S. Federici, T., Peyre, S.. De Angelis, C., Bonanno, G., T| ogliani, T.
Bordi, C. see Lahner, E. Pileri, S., Tura, S. & The Italian Gastric Lymphoma Study
Borque, M.J. see Moreno-Monteagudo, J.A. Group. The importance of endoscopic ultrasonography in the
Borrelli, O. see Franzese, A. management of low-grade gastric mucosa-associated lymphoid
Borro, P. see Bilardi, C. tissue lymphoma, 1715
Bortolotti, M., Coccia, G., Grossi, G. & Miglioli, M. The treatment of Calvet, X., Ducons, J.. Guardiola, J., Tito, L., Andreu, V., Bory, F.
functional dyspepsia with red pepper, 1075 Guirao, R. & The Group for Eradication Studies from Catalonia,
Bory, F. see Calvet, X. \ragon (GRESCA). One-week triple vs. quadruple therapy tor
Botta, F. see Giannini, E. Helicobacter pylori infection a randomized trial, 1261
Bouley, C. see Marteau, P. Calvet, X., Sanfeliu, I.. Musulen, E., Mas, P., Dalmau, B., Gil. M..
Bouvier, A.-M. see Faivre-Finn, C. Bella, M.R., Campo, R., Brullet, E., Valero, C. & Puig, J.
3ouvier, M. see Marteau, P. Evaluation of Helicobacter pylori diagnostic methods in patients
bowel disorders, 1867 with liver cirrhosis, 128 3
bowel habit, 759 Calvet, X. see Vallve, M.
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 21
2126 INDEX
Calvi, A. see Barabino, A. cell proliferation, 6 33
Calza, L. see Manfredi, R. CEM cells, 1021
Camartino, G. see Sambuelli, A. Chan, A.O.O. see Wong, W.-M.
Camilleri, M., Heading, R.C. & Thompson, W.G. Consensus report: Chan, C.K. see Hung, W.K.
clinical perspectives, mechanisms, diagnosis and management Chan, C.K. see Wong, W.-M.
of irritable bowel syndrome, 1407 Chan, C.K. see Wong, W.M.
Camilleri, M. see Cremonini, F. Chan, C.K. see Xia, H.H.-X.
Camilleri, M. see Kuo, B. Chan, F.K.L. see Wu, J.C.Y.
C-aminopyrine breath test, 717 Chan, F.K.L. see You, J.H.S.
Cammarota, G. see Di Caro, $ Chan, H.L.Y. see Cheng, A.S.L.
Campanone, A. see Gaeta, G.B. Chan, K.A. see Chang, C.H.
Campbell, M. see Hallerbéack, B. Chan, T.Y.K. see You, J.H.S.
Campbell, S., Kingstone, K. & Ghosh, S. Relevance of thiopurine Chang, C.H., Chen, K.Y., Lai, M.Y. & Chan, K.A. Meta-analysis:
methyltranslerase activity in inflammatory bowel disease ribavirin-induced haemolytic anaemia in patients with chronic
patients maintained on low-dose azathioprine, 389 hepatitis C, 1623
Campieri, M. see Mimura, T. Chang, C.S. see Poon, S.K.
Campieri, M. see Rizzello, F. Chang, F.-Y. see Luo, J.-C.
Campo, R. sec Calvet, X. Chang, K.K. see Yee, Y.K.
campylobacter, 1037 Chang, L. see Mayer, E.A.
cancer registries, 353 Chapman, M.A.S. see Hulin, S.J.
cancer screening, 41 Chapman, R.W. see Mitchell, S.A.
Candelli, M. see \rmuzzi, A. Chasen, R. see Rex, D.K.
Candelli, M. see Di Caro, S. Chaussade, S. see Abitbol, V.
Cange, L., Johnsson, E., Rydholm, H., Lehmann, A., Finizia, C., Chayama, K. see Ito, M.
Lundell, L. & Ruth, M. Baclofen-mediated gastro-oesophageal Chen, C.L., Orr, W.C., Verlinden, M.H., Dettmer, A., Brinkhoff, H..,
acid reflux control in patients with established reflux disease, Riff, D., Schwartz, S., Soloway, R.D., Krause, R., Lanza, F. &
S69 Mack, R.J. Efficacy of a motilin receptor agonist (ABT-229) for
Cann, P.A. see Mansfield, J.C. the treatment of gastro-oesophageal reflux disease, 749
Capelli, G. see Cremonini, F. Chen, C.-Y. see Luo, J.-C.
Caprilli, R., Viscido, A. & Guagnozzi, D. Review article: biological Chen, G.H. see Poon, S.K.
agents in the treatment of Crohn’s disease, 1579 Chen, J.-H. see Sheu, B.-S.
capsaicin, 1075 Chen, K.Y. see Chang, C.H.
Capurso, G. see \nnibale, B. Chen, T.-K. see Liao, C.-C.
Caratto, E. see Zentilin, P. Chen, W.H. see Wong, W.-M.
carbon-labelled breath tests, 1977 Cheng, A.S.L., Chan, H.L.Y., Leung, N.W.Y., Liew, C.T.. To, K.F..
carcinoma Lai, P.B.S. & Sung, J.J.Y. Expression of cyclooxygenase-2 in
cardiovascula chronic hepatitis B and the effects of anti-viral therapy, 251
cardiovascular disease, 1945 Cheng, C.S. see Ng, F.H.
cardiovascular prophylaxis, 497 Cheung, H.K.L. see Xia, H.H.-X.
carotenoids, 985 Chey, W.D. see Ladabaum, U.
Caruana, P. see Annibale, B. Chi, C.-H. see Sheu, B.-S.
Caruana, P. see Lahner, E. Chiang, T.-C. see Liao, C.-C.
carvedilol, 37 3 Chiarbonello, B. see Giannini, E.
case-control analysis, children, 951, 1125, 1503, 1663, 2073
case-control study, 497 Chinese, 465, 521, 2037
CASC—CYOSSOVE! study, 875 Chinn, D. see Rubin, G.
Casetti. T. see Rizzello, FP. Chiodo, F. see Manfredi, R.
Caspary, W.F. see Braden, B. Chiu, Y.-L. see Huang, J.-Q.
Castell, D.O. see Tutuian, R. Choi, L.J., Jung. H.C., Choi, K.W., Kim, J.H., Ahn, D.S., Yang, U.S..,
Castellano, E. see Barabino, A. Rew, J.S., Lee, S.I., Rhee, J.C., Sik Chung, I., Chung, J.M. &
Castiella, A. see Elizalde, J.1. Hong, W.-S. Efficacy of low-dose clarithromycin triple therapy
Castiglione, G.N. see Rizzello, F. and tinidazole-containing triple therapy for Helicobacter pylori
Castro, A. see Moreno-Monteagudo, J.A. eradication, 145
Castro, M. see Barabino, A. Choi, I.J. see Kim, J.S.
Cazzato, I.A. see Armuzzi, A. Choi, K.W. see Choi, IJ.
celecoxib, 819 cholesterol, 577
celrlT ] diwviicshi on, 6 33 Christensen, E. see Schiodt, F.V.
2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2123-2148
INDEX
chromogranin A, 1367 Conio, M. see Zentilin, P.
chronic, 1623, 1633 constipation, 1701
chronic hepatitis B, 251 onstipation, 603
chronic hepatitis C, 243, 1091, 1555 contrast agent, 217
chronic hepatitis, 717 controlled trial, 27, 1649
chronic liver disease, 361 Cooney, R. see Sengupta, S.
chronic pancreatitis, 2097 Corazzi, A. see Ortiz, R.A.M.
Chrysos, E. see Athanasakis, E. corpus gastritis, 887
Chung, J.M. see Choi, LJ. Corrado, G. see Franzese, A.
ciclosporin, 181, 1021, 1503, 2061 ‘orrea, P. see Rugge, M.
Ciociola, A.A. see Gardner, J.D. orticosteroids, 647, 1241, 1519, 1939
Ciociola, A.A. see Orenstein, S.R. ortisol, 1021
Ciociola, A.A. see Robinson, M. Cosme, A. see Elizalde, J.1
ciprofloxacin, 909 ost analysis, 1529, 2089
cirrhosis, 985 ost-effectiveness, 1469
cisapride, 297, 743, 951, 1641 ost-effectiveness analysis, 41
clarithromycin, 137, 145, 569, 793, 1047 ost-minimization analysis, 1491
clarithromycin resistance, 1933, 2073 osts, 1217
Claversal Foam, 415 o-twin control analysis, 975
Clemens, C.H.M., Samsom, M., Van Berge Henegouwen, G.P.., ‘oulshed, D.S. see Eslick, G.D.
Fabri, M. & Smout, A.J.P.M. Effect of alosetron on left colonic ‘OX activity, 847
motility in non-constipated patients with irritable bowel ‘OX-2 inhibitor, 847
syndrome and healthy volunteers, 993 Crafa, P. see Bashir, S.
Clinard, F. see Faivre-Finn, C. ‘remonini, F., Di Caro, S., Nista, E.C., Bartolozzi, F., Capelli, G.
clli nical practice, 487 Gasbarrini, G. & Gasbarrini, A. Meta-analysis: the effect of
clli nical remission, 1233 probiotic administration on antibiotic-associated diarrhoea,
c7li nical trial, 1327 1461
cllo nidine, 945 ‘remonini, F., Mullan, B.P., Camilleri, M.. Burton, D.D. & Rank,
Coakley, A.J. see Lamb, E.J. M.R. Performance characteristics of scintigraphic transit
Coccia, G. see Bortolotti, M. measurements for studies of experimental therapies, 178]
coeliac disease, 1333 remonini, F. see Armuzzi, A
Cohen, A.F. see Kamerling, I.M.C. ‘remonini, F. see Di Caro, S.
Cohen, R.D. The quality of life in patients with Crohn's disease, ‘rispino, P. see Paoluzi, O.A.
1603 ‘rocella, L. see Della Monica,
Colin, R. for the HEPYLOG Investigator Study Group. Duodenal Crocombe, W. see Mason, J.
ulcer healing with 1-week eradication triple therapy followed, ‘rohn's disease, ‘i, 79,
or not, by anti-secretory treatment: a multicentre double-blind 1509, 1519, 1579,
placebo-controlled trial, 1157 ronkhite-Canada syndrot
colitis, 181 rypt branching,
Colle, I. see Van Vlierberghe, H. rypt fission, 6
Collings, K.L., Rodriguez-Stanley, S., Proskin, H.M., Robinson, M ‘sel, H. see Kraus, M.R
& Miner Jr, P.B. Clinical effectiveness of a new antacid chewing ‘ucchiara, S. see Barabino, A.
gum on heartburn and oesophageal pH control, 2029 ‘ucchiara, S. see Franzese, A.
colon, 603 ‘uillerier, E. see Marteau, P.
colon carcinoma, 353 Cunliffe, R.N. & Scott, B.B. Review article: monitoring for drug
colon transit, 1781 side-effects in inflammatory bowel disease, 647
colonic delivery, kisi -urea breath test, 787
colonic fluid absorption, 623 ‘urran, R. see Massironi, S
colonic motility, 623, 985 cyclo-oxygenase, 847
colonic transit constipation, 759 cyclo-oxygenase-2, 251
colonic transit time, 587 cyclo-oxygenase-2 inhibitor, 2089
colonoscopy, 937, 1197, 1327 CYP2C19 extensive metabolizer, 1811
collo rectal cancer, 333, 1197 1225 CYP2C19 genotype, 837
combined treatment, 243 cytokines, 399
complementary therapy, 197 cytosolic hepatic function, 1977
complications, 27, 1547
concanavalin-A, 633 > Dalhoff, K. see Schmidt, L.E.
D’Alincourt, A. see Gournay, J.
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 212
2128 INDEX
Dalke, D. see Yacyshyn, B.R. Dhillon, A.P. see Gordon, F.H.
Dalmau, B. see Calvet, X. Dhir, V. see Laine, L.
D’Ambra, G. see Lahner, E. Di Caro, S., Ojetti, V.. Zocco, M.A., Cremonini, F., Jartolozzi, F.,
D’Arienzo, A Candelli, M., Lupascu, A., Nista, E.C., Cammarota, G. &
Dawson, C. see Langmead, L. Gasbarrini, A. Mono, dual and triple moxifloxacin-based
Day, A. see Shaw, LS. therapies for Helicobacter pylori eradication, 527
Angelis, C. s¢ e Caletti, G. Di Caro, S. see Cremonini, F.
Argila, C.M. see Elizalde, J.1. Di Giulio, E. see Annibale, B.
» Block, C.E.M., De Leeuw, I.H., Bogers, J.J.P.M., Pelckmans, Di Giulio, E. see Lahner, E.
P.A., leven, M.M., Van Marck, E.A.E., Van Hoof, V., Maday, E., Di Martino, V. see Goulenok, C.
Van Acker, K.L. & Van Gaal, L.F. Helicobacter pylori, parietal Di Matteo, G. see Rizzello, F.
cell antibodies and autoimmune gastropathy in type 1 diabetes Di Nardo, G. see Franzese, A.
mellitus, 28 1] Di Pietro, C. see Bazzoli, F.
Boer, W.A. see Laheij, R.J.F. diabetes, 281, 951
» Giacomo, C. see Barabino, A. diabetic gastropathy, 945
Joon, J.N. sec Van Hecken, A. diagnosis, 683, 813, 1407, 1443
le Jong-van den Berg, L.T.W. See Klok, diagnosis and eradication, 533
y alla, | diagnostic, 1283
> Leeuw, | » Block, C.E.M. diagnostic accuracy, 787
» Lepeleire see Van Hec ken a: urhoea, 595, 769, 1461, 1709
> Lorenzo \rmuzzi, A. diclofenac, 819
> Luca, I. see Bazzoli, F. alisils¢t al ulcerative colitis, 415
» Micheli razzoni, M. Distrutti, E. Fiorucci, S., Hauer, S.K., Pensi, M.O., Vanasia, M. &
> Pauw, M Sloots, C.E.]. Morelli, A. Effect of acute and chronic levosulpiride
» Pedro, A \Voreno-Monteagudo, J.A. administration on gastric tone and perception in functional
» Ponti, F., Netzer, R. DeGiorgio, M.C. Bateson, H.K. Parsons, P. dyspepsia, 61 3
& Inauen, W. Letters to the Editors, 643 Dito, L. see Franzese, A.
» Schryver, A.M.P., Andriesse, G.I., Samsom, M., Smout, Dixon, M.F. see Rugge. M.
\.J.P.M., Gooszen, H.G. & Akkermans, L.M.A. The effects of the Doldan, I. see Sambuelli, A.
specific 5HT, receptor agonist. prucalopride, on colonic Domareva, I. see Isakov, V.
motility in healthy volunteers, 603 Domenech, E., Garcia-Planella, E., Bernal, 1., Rosinach, M., Cabre.
> Sena, R. see E., Fluvia, L., Boix. J. & Gassull, M.A. Azathioprine without
> Souza, C.A.F. see Ortiz, R.A.M. oral ciclosporin in the long-term maintenance of remission
> Vos, M. see Van Vlierberghe, H. induced by intravenous ciclosporin in severe, steroid-refractory
de’Angelis, G.L. see Barabino, A. ulcerative colitis, 2061
decision analysis, 41, 727, 1003 domperidone, 951
lecision tree, 2089 Domschke, W. see Ullerich, H.
Defarges, V. see Boixeda, D. Donoghue, S. see Gordon, F.H.
Deguer, M. see Ortiz, Dorn, G.H. see Ofman, J.J.
Delanghe, J. see Van Vlierberghe, H. Dorr, F.A. see Yacyshyn, B.R.
Della Monica, P.. Lavagna, A., Masoero, G., Lombardo, L.
Crocella, | & Pera, A.Effectiveness of Helicobacter pylo | Draganov, V. see Tankova, L.
eradication treatments in a primary care setting in Italy, 1269 drug development, 343
Delle Fave, G. see Annibale, B drug interaction, 79, 1539
Delle Fave, G. see Lahner, E. drug monitoring, 205 3
Demetriou, A.A. see Pazzi, P. drug therapy, 27
Dent, J. see Mallertheiner, P. Drummond, M. see Mason, J.
Depre, M. see Van Hecken, A. Ducons, J. see Calvet, X.
depression, 1091 Dutfett, S. see Mason, J.
Derbyshire, S.W.G. see Mayer, Dulbecco, P. see Bilardi, C.
Desager, J.P. see Dewit, O. Dulbecco, P. see Zentilin, P.
Dettmer, A. see Chen, C.L. Duley, J. see Ansari, A.
Devault, K. see Kovacs. T.0.G. duodenal | disorders, 799, 1209, 1955
development, 799 duodenal ulcer scar, 275
Dewit, O., Vanheuverzwyn, R., Desager, J.P. & Horsmans, Y. duodena | ulcer, 1137, 1157, 1431
Interaction between azathioprine and aminosalicylates: an in duodenal l ulcer, 275, 303, 779
vivo study in patients with Crohn's disease, 79 Dupas, B. see Gournay, J.
2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2123-2148
INDEX 2929
Dupas, J.-L. see Abitbol, V. esomeprazole, 1301
Dwarakanath, A.D. see Rubin, G. essent ial fatty acids, 1125
DXA, 1519 Evans 3.K. see Hawkes, N.D.
Dynder, A. see Van Hecken, A. . see Huilgol, V.
dysentery, 1709 Evenepoel, P. see Geboes, K.P.
dyspepsia, 105, 819, 1075, 1491, 1709
Faas, H., Steingoetter, A., Feinle. C., Rades, T., Lengsfeld, H..
Earnest, D.L. see Tougas, G. iDOoCs iger, P., Fried, M. & Schwizer, W. Effects of meal
Ebert, M.P.A. & Malfertheiner, P. Review article: pathogenesis of consistency and ingested fluid volume on the intragastric
sporadic and familial gastric cancer — implications for clinical distribution of a drug model in humans—a magnetic
management and cancer prevention, 1059 resonance imaging study, 217
ECL cell hyperplasia, 1367 bri, M. see Clemens, C.H.M.
economic, 1217, 1469 bris, P., Pilotto, A.. Bozzola, L., Tositti, G., Soffiati, G.. Mantrin,
effectiveness, 1269 V. & de Lalla, F. Serum pepsinogen and gastrin 1l evels in HI\
Eggo, M.C. see Hulin, S.J. positive patients: relationship with CD4+ cell count and
Ehrenpreis, E.D. see Ginsburg, P.M icobacter pylori infection, 807
Eisen, G.M. see Goldstein, J.1 He a ids, 587
elderly, 683 markers, 675
electrogastrography, 119, 129, 951 aessel, H.M. see Orenstein. S.R.
Elizalde, I. see Elizalde, J.1. 1047
Elizalde, J.1. Piqué, J.M., Moreno, V., Morillas, J.D.,. Elizalde, I., J. see Faivre-Finn, C.
Bujanda, L., De Argila, C.M., Cosme, A., Castiella, A. & Ros, E. .C.. Bouvier, A.-M., Mitry, E., Rassiat. E., Clin
(for the Group of Study of Oesophageal. Gastric Diseases from the J}. Chemotherapy rr 3 col]o n cance.r . in . a wPep ll-LdA elin
Spanish Gastroenterological Association). Influence of ch population: is i - or over-prescribed? 35
Helicobacter pylori infection and eradication on blood lipids and isco, G., Zinicola, R. & Forbes, A. Review article:
fibrinogen, 577 immunosuppressants in distal ulcerative ¢
Ell, P.J. see Tuleu, C. A.L.
Ellis, C. see Tinto, A.
El-Serag, H.B., Olden, K. & Bjorkman, D. Health-related quality of
life among persons with irritable bowel syndrome: a systematic
review, 1171 R.J.. Menconi, M.] Keates, A.C. & Kelly. C.P.
Emmanuel, A.V., Roy, A.J., Nicholls, T.J. & Kamm, M.A. P-Glycoprotein-170 inhibition significantly reduces cort
Prucalopride, a systemic enterokinetic, for the treatment of and ciclosporin efflux from human intestinal epithelial
constipation, 1347 and T lymphocytes. 1021
Emmanuel, A.V. see Van Den Bogaerde, J. 3. See Zulu, |
endoscopic ultrasonography, 1715 see Zentilin, P
enema, 27 see Giannini, E.
energy-deficiency, 325 R. see Otman, J.J.
Enghofer, M. see Braden, B. \ST trial investigation <obinson, M.
enteric-coated aspirin, 168 3 ‘agan, B G. see Kane, S.\
enterokinetic, 603, 759 kins, R. see Zulu, I.
Entsuah, L.K. see Bashir, S. Federici, T. see Caletti, G
environmental factors, 975 ]F einle|, C. see Faas, H.
epidemiology, 1407, 1519, 1709 Felaco, F.M. see Gaeta, G.B
epithelial transport, 1571 Felsenberg, D. see Stockbriigger.
epithelium, 633 Felt-Bersma,. R.J.F. see Sloots, C.E.].
eradication, 153,515, 1157, |F elt1 bower, - R>.? see AMf.a son, J}
eradication treatment, 507 female, 1877
ERCP, 727 Fendrick, A.M. see Ladabaum, U.
Ernst, E. see Thompson Coon, J. Fennerty. M.B. see Ofman, J.J.
erosive oesophagitis, 445, 2043 Ferguson, A. see Stockbriigger, R.W.
erosive reflux oesophagitis, 735 fermented milk, 587
erythromycin, 1563 Fernandez-Bermejo, M. see Moreno-Monteagudo, J.
Eslick, G.D.. Coulshed, D.S. & Talley, N.J. Review article: the Ferraro. G. see Bashir, S.
burden of illness of non-cardiac chest pain, 1217 Ferraz, ].G.P. see Ortiz, R.A.M.
Eslick, G.D., Yan, P., Xia, H.H.-X., Murray, H., Spurrett, B. & Ferreira, I.J. see Serrano, P.
Talley, N.J. Foetal intrauterine growth restrictions with Fevery, J. see Van De Casteele, M.
Helicobacter pylori infection, 1677
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2
2130 INDEX
Feydt-Schmidt, A., Riissmann, H., Lehn, N., Fischer, A., Antoni, Fuentes, J. see Lanas, A.
[., Stork, D. & Koletzko, S. Fluorescence in situ hybridization vs. Fujioka, T. see Murakami, K.
epsilometer test for detection of clarithromycin-susceptible and Fujishiro, H. see Adachi, K.
clarithromycin-resistant Helicobacter pylori strains in gastric Fukushima, Y. see Saitoh, T.
biopsies from children, 2073 Fumagalli, A. see Giannini, E.
fibrinogen, 577 functional constipation, 1347
fibrosis, 71 functional dyspepsia, 613, 959, 1641, 1805
Filice, G. see Gaeta, G.B Fung, F.M.Y. see Hung, W.K.
Finizia, C. see Cange, L. Fung, F.M.Y. see Wong, W.M.
Fiocca, R. see Rugge, M. Fung, F.M.Y. see Xia, H.H.-X.
Fioramonti, J. see Picard, C. Fung, K. see Orenstein, S.R.
Fiorucci, S. see Distrutti, E. Fung, K. see Robinson, M.
Fischer, A. see Feydt-Schmidt, furazolidone, F277
FitzGerald, A.J. see Sasaki, M. uruta, T., Shirai, N., Xiao, F., Takashima, M. & Hanai, H. Effect of
Fitzgerald, L. see Mayer, E.A. Helicobacter pylori infection and its eradication on nutrition, 799
Fitzgerald, S. see Robinson, M. Furuta, T. see Shirai, N.
l'remaine, W.]J. Fusaroli, P. see Caletti, G.
Futagami, S., Hiratsuka, T., Wada, K., Tatsuguchi, A., Tsukui, T.,
Flockhart, D.A. see Marino, G. Miyake, K., Akamatsu, T., Hosone, M., Sakamoto, C. &
Floyd, D. see Khan, Z Kobayashi, M. Inhibition of Helicobacter pylori-induced cyclo-
flumazenil oxygenase-2 aggravates NSAID-caused gastric damage in
fluorescen Mongolian gerbils, 847
fluorescen situ hybridization, 207 3
V1 ] GABA ,, S69
gabexate mesilate, 1791
n,E. Gaeta, G.B., Precone, D.F., Felaco, F.M., Bruno, R., Spadaro, A.,
Stornaiuolo, G., Stanzione, M., Ascione, T., De Sena, R.,
rowth restriction, 1677 Campanone, A., Filice, G. & Piccinino, F. Premature
Fontana, M. see Barabino, A discontinuation of interferon plus ribavirin for adverse effects:
food allergens. 1903 a multicentre survey in ‘real world’ patients with chronic
for the HEPYLOG Investigator Study Group. see Colin, R. hepatitis C, 163?3
Forbes, A. see Falasco, G. Gaia, C. see Netzer, P.
Ford, J. see Shaw, L.S gallbladder, 129
Fordtran, J. s logenauer, C. gallbladder volume, 1801
Forman, D. see Mason, J. Galmiche, J.P. see Gournay, J.
Fossi, S. see Bazzoli. | Gambaro, C. see Bilardi, C.
Foster, R. see Poullis, A. Gambaro, C. see Zentilin, P
fractures, 1519 gamma scintigraphy, 1771
Frame, M. see Hart, A.L. Gandullia, ») P. see Barabino, A.
Franzese, A., Borrelli, O., Corrado, G., Rea, P., Di Nardo, G., Grand- Ganskaya, Z. see Isakov, V.
inetti, A.L., Dito, L. & Cucchiara, S$.D omperisi mdoreo efnfeceti ve Garcia-Buey, L. see Moreno-Monteagudo, J.A.
than cisapride in children with diabetic gastroparesis, 951 Garcia-Plaza, A. see Boixeda, D.
Fraser, A.G.. Morton, D., McGovern, D., Travis, S. & Jewell, D.P. Garcia-Planella, E. see Domenech, E.
he eflicacy of methotrexate for maintaining remission in Gardner, J.D., Ciociola, A.A., Robinson, M. & Mclsaac, R.L.
inflammatory bowel disease, 69 3 Determination of the time of onset of action of ranitidine and
Fraser, A.G., Orchard, T.R., Robinson, E.M. & Jewell, D.P. Long famotidine on intra-gastric acidity, 1317
term risk of malignancy after treatment of inflammatory bowel Gardner, J.D., Perdomo, C., Sloan, S., Hahne, W.F., Barth, J.A..
disease with azathioprine, 1225 Rodriguez-Stanley, S. & Robinson, M. Integrated acidity and
Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. Hiatal rabeprazole pharmacology, 455
hernia is the key factor determining the lansoprazole Gardner, J.D., Rodriguez-Stanley, S., Robinson, M. & Miner Jr, P.B.
dosage required for effective intra-oesophageal acid Cisapride inhibits meal-stimulated gastric acid secretion and
suppression, 881 post-prandial gastric acidity in subjects with gastro-
Frazzoni, M., De Micheli, E., Grisendi, A. & Savarino, V. oesophageal reflux disease, 1819
Lansoprazole vs. omeprazole for gastro-oesophageal reflux gas, 1641
disease: a pH-metric comparison, 35 Gasbarrini, A. see Armuzzi, A.
Freyne, P.J. see Mahmud, N. Gasbarrini, A. see Cremonini, F.
Fried, M. see Faas, H. Gasbarrini, A. see Di Caro, S.
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2123-2148
INDEX
Gasbarrini, G. see Armuzzi, A. Ghoos, Y Y. see Geboes, K.P.
Gasbarrini, G. see Cremonini, F. Ghosh, S . see Arnott, [.D.R.
Gaspari, M. see Yacyshyn, B.R. Ghosh, SS. see Campbell, S.
Gasperi, V. see Perri, F. Ghosh, S. see Khan, Z.
Gassull, M.A. see Domenech, E. Giafler, M.H. see Mansfield, J.C.
gastric, 799 Giannini, E., Fasoli, A., Chiarbonello, B., Malfatti, F., Romagnoli,
gastric acidity, 875 P., Botta, F., Testa, E., Polegato, S., Fumagalli, A. & Testa, R
gastric cancer, LO5S9 ‘C-Aminopyrine breath test to evaluate severity of disease in
gastric carcinoid, 1367 patients with chronic hepatitis C virus infection, 717
gastric disorder, 1209, 1955 Giardiello, F.M. see Trimbath, J.D.
gastric emptying, 119, 945, 1 . F. see Bashir, S.
gastric mucosal atrophy, 1249 Gibson J. A. see Green, J.R.
gastric outlet obstruction, 1203 Gil, A. see Sambuelli, A
gastric perception, 613 Gil. M. sec Calvet, me
gastric pH, 875 Ginsburg, P.M. & Ehrenpreis, E.D. A pilot study of thalidomide for
gastri ulcer, 779, 1137, 1431 patients with symptomatic mesenteric panniculitis, 2115
gastric ultrasound, 951 Gionchetti, P. see Mimura, 1
gastrin, 503, 299. 1723, 1805 Gionchetti, P. see Rizzello, |
gastritis, 159 Gisbert, J.P. see Vallve, M
gastritis, 1923 Gisbert, J.P. & Pajares, J.M. Review article: He
gastroduodenal motility, 1563 ‘rescue’ regimen when proton pump inhibitor-l
gastrointestinal, 1059, 1781 apies fail, 1047
gastrointestinal bleeding, 779, 2037 Gisbert, J.P. & Pajares, J.M. Review article: Helicobacter pylo
gastrointestinal disorders, 969 infection and gastric outlet obstruction prevalence
gastrointestinal endoscopy, 1003 infection and role of antimicrobial treatment, 1203
gastrointestinal haemorrhage, 1945 Gissi, A. see Barabino, A
gastrointestinal haemostasis, 1003 Glebas, K. see Novick, ]
gastrointestinal hormones, 119 glidomorphine, 66 3
gastrointestinal oncology 1197 Glise, H. see Hart, A.l
gastrointestinal oncology, 1209, 1843 glucagons, 111
gastrointestinal tract, 6 33 ree diet, 1333
gastro-oesophageal reflux disease, 17, 261 £35, 473, 479, Golf, J. see Yacyshyn, B.R
735, 743, 749, 819, 869, 899, 1143 1309, 1469, Goldstein, J.L.. Eisen, G.M. Burke, T.A., Pena, B.M., Lefkowith, J.
1655. 3795, 2029, 2043 & Geis, G.S. Dyspepsia tolerability from the patients’
gastroparesis, 1341 perspective: a comparison of celecoxib with diclofenac, 819
gastroscopy, 1O11 Goldwater, D.R. see
Gatta, L. see Palli, D. Gonzalez, QO. see Sambuelli, A.
Gavin, M.W. see Sonnenberg, A. Goodlad, R.A. see Sasaki, M.
Geboes, K.P., Maes, B., Luypaerts, A., Evenepoel, P., Rutgeerts, P Gooszen, H.G. see De Schryver, A.M.P.
Ghoos, Y. & Geypens, B. Magnesium chloride slows gastric Gorard, D.A. see Bhat, K.
emptying, but does not affect digestive functions, 1571 Gordon, F.H., Hamilton, M.1., Donoghue, S.. Greenlees, C., Palme:
Geis, G.S. see Goldstein, J.L. r., Rowley-Jones. D Dhillon AP: \mlot, P.L. & Pounder,
Gendre, J.P. see Abitbol, V. R.E. A pilot study of treatment of active ulcerative colitis with
gene, LOSSY natalizumab, a humanized monoclonal antibody to alpha-4
general practice, 1067 integrin, 699
genetic and familial-environmental effects, 975 Gottesdiener, K. see Van Hecken, A.
geneti counselling, 1843 Goulenok, C., Bernard, B., Cadranel, J.F., Thabut, D., Di Martino, V.,
genetic testing, 1843 Opolon, P. & Poynard, T. Flumazenil vs. placeo in hepatic
Genta, R.M. see Rugge, M. encephalopathy in patients with cirrhosis: a meta-analysis, 361]
Georgopoulos, S.D., Ladas, $.D., Karatapanis, S., Triantafyllou, K.., Gournay, J., Tchuenbou, }., Richou, C., Masliah, C., Lerat, F., Dupas
Spiliadi, C., Mentis, A., Artikis, V. & Raptis, S.A. Effectiveness of B., Martin, T., Nouel, J.F., Schnée, M., Montigny, P., D’Alincourt,
two quadruple, tetracycline- or clarithromycin-containing, \., Hamy, A., Paineau, J., Le Néel, J.-C., Le Borgne, J. &
second-line, Helicobacter pylori eradication therapies, 569 Galmiche, J.P. Percutaneous ethanol injection vs. resection in
Gerhardt, M.F. see Marteau, P. patients with small single hepatocellular carcinoma: a
Gertz, B. see Malchow, H. retrospective case-control study with cost analysis, 1529
Geypens, B. see Geboes, K.P. Graffner, H. see Hart, AL.
Ghatei, M.A. see Sasaki, M. Graffner, H. see Stockbriigger, R.W.
© 2002 Blackwell Science Ltd, Aliment Pharmacol Ther 16, 2123-2148
Graham, D.Y. see Malfertheiner. P. Harper, A. see Bhat, K.
Graham, D.Y. see Verghese, V.J. Hart. A. & Kamm, M.A. Review article: mechanisms of initiation
Granalo, s\. § razzi, ©. and perpetuation of gut inflammation by stress, 2017
Grandinetti, A.L. see Franzese, A. Hart, A.L., Stagg, A.J., Frame, M., Grafiner, H., Glise, H., Falk, P. &
grauseti Kamm, M.A. Review article: the role of the gut flora in health
Grant, ! and disease, and its modification as therapy. 1383
Grant, G Haruma., K. see Ito, M.
Graziano Hashimoto, T., Adachi. K., Ishimura, N., Hirakawa, K.. Katsube.
Mansfield, J.C.. Gibson, J.A.. Kerr, G.D. & Thornton, I.. Kurotani, A.. Hattori, S. & Kinoshita, Y. Safety and efficacy
{ comparison of balsalazide, 6.75 g daily. of glucagon as a premedication for upper gastrointestinal
3 g daily, in patients with newly diagnosed endoscopy—a comparative study with butyl scopolamine
erative colitis, 61 bromide, 111
Green, | Hassan, C. see \nsari, A.
Greenlees Hattori. S. see Hashimoto, ’
Grehn, S Hattori, T. see Rugge, M.
Grieco, 1H auer, S.K. see Distrutti, E.
Gritliths Hawkes, N.D.. Rhodes, J., Evans, B.K.. Rhodes, P., Hawthorne,
Grimaud \.B. & Thomas, G.A.O. Naloxone treatment for irritable bowel
Grisend syndrome a randomized controlled trial with an oral
Granno, ¢ formulation, 1649
Grossi, ¢ Hawkey. C.J. see Stack, W.A.
Grossi, G. Hawkey, G.M. se Stack, W.A.
Groupo f Stuc O}y phageal, Gastric Diseases from the Spanish Hawkins, C. see Langmead, L.
Gastroenterological Association, see Elizalde, J.1. Hawthorne, A.B. see Hawkes, N.D.
Hayashi, P.H. & Trotter, J.F. Review article: adult-to-adult right
hepatic lobe living donor liver transplantation, 18 33
Hayes, P.C. see Tripathi, D.
Grunow, J.! Orenstein, S.R Heading, R.C. see Camilleri, M.
Gschossmann Holtmann, G healing, 1157
Gu, Q. see W th, 1469
Guagnozzi health economics, 559
Guardio health status, 1101
Guillen seeking behaviour, 1217
)
Guirao, R health-related quality of life. 1101
health-seeking behaviour, 2081
wy volunteers, 819
Hearing. S.D. see Shaw, LS.
heartburn, 435, 479, 899, 1309,
H-recept Hegedus. R. see Robinson, M
:
Haapiainen, R Kokkola, Helicobacter pylori therapy, 1143
haemochromatosis, 196 3 Helicobacter pylori, 105, 137, 145, 153, : 2S Lou, 2a,
Hahne, W.1 Gardner, J.D. we. 4 . 545. » 569. S77,
Hallerback, B Bommelaer, G., Bredberg, E.. Campbell, M.. », 847, 887, 1015, 1037, 1047,
Hellblom, M uritsen, K., Wienbeck, M. & Holmgren, L.-L. . 1143, 1149, 1163, 1203, 1241, 1261. 1269, 1277,
Dose finding study of mosapride in functional dyspepsia: a 1291, 1301, 1431, 1443, 1449, 1457, 1663, 1677.
placebo-controlled. randomized study, 959 L669; 17125, 1725. 1733. 1805, 1935,.2067;.2075
fallert, C., Grant, C. Grehn, S., Graénn6, C., Hulten, S., Midhagen, Hellblom, M. see Hallerbéick. B.
G., Strom, M., Svensson, H. & Valdimarsson, T. Evidence of Hellman, R.S. see Huilgol, V.
poor vitamin status in coeliac patients on a gluten-free diet fo1 Helwig, U. see Mimura, T.
ohne eee
10 vears, 1333 hepapoietin, 235
Hamelin, B. see Svedberg, P. hepatic encephalopathy, 361
Hamilton, M.I. see Gordon, F.H. hepatic resection, 1529
Hamm, L. see Mayer, E.A. hepatic venous pressure gradient, 37 3
Hamy, A. see Gournay, J. hepatitis C virus, 717
Hanai, H. see Furuta, T. hepatitis C, 381, L611, 1623; 1633
Hanai, H. see Shirai, N. hepatocellular, 1
Hanauer, S.B. see Sytgat, G.N.J. hepatocellular carcinoma, 251, 1529
2002 Blackwell Science Ltd. Aliment Pharmacol Ther 16, 2123-2148